Trump’s Drug Price Ultimatum has set the pharma firm

Pharmaceutical companies are shouting to respond to the new ultimatum demanding a “binding commitment” to reduce the prices of drugs of US President Donald Trump.??

White House said Thursday that President Trump Sent to the letter They should take the 1 Major chief pharmaceutical companies that outline the steps they have taken to reduce the cost of US drugs by September.

They were told that if they refuse to “take a step,” the government would deploy from the prices of continuous abusive drugs in the arsenal, saying what the solution could be in its “arms”.

Were companies receiving letters Abiy, Emjin, AstrageneccaBOINGERINGER Inglehim, Bristle-Myers Ski, Ely LilyEMD Seronon, Roche ‘S Assistant Jennenta, Gilliad, GSK, Johnson and Johnson, Merk, Novartis, Novo Nordis, Fiezer, Reganneron And Sanofi??

Healthcare stocks fell on Friday after the extensive market loss as investors digest Trump’s improved trade rates. At 11:15 at 11:15 London Time (AM AT), the shares of Vegvi-Maker Novo Nordisk fell by 5% in the morning trade.

Companies were informed that they should provide MFN prices to all medical patients, US health programs for low -income patients.

They were also told not to give medicines to other developing markets at better prices than those offered in the United States and they should directly sell medicines to American patients, which will reduce the pharmacy. Middlemen known as the Pharmacy Benefit Manager (PBMS).

Trump has long been cheating on pharmaceutical companies that are in unjust pricing methods, in the past, saying that they had planned to bring US prices by 80%.

In May, the President signed the executive order Less drug costs Some of the US drug prices bind to people abroad under MFN policy.

US Consistently pays the most in the world For many prescription drugs, some of the US is a very complex and broken anti -reflex system and lack of control of national prices.

The latest announcement is also a pharmaceutical industry Call for clarity At potential industry-wide rates. Trump had earlier warned that these could run by 200 up to 200 percent.

Many companies still have shared that they agree with some of Trump’s concerns.

Astrajenka’s CEO Pascal Soriot said on Tuesday that Anglo-Sweezed firm is. Close contact More comprehensively with the US administration about MFN policy and investment in US production. Last week, after many other pharma companies, the US announced a plan to invest $ 50 billion in the United States.

“There are some issues around the prices. I personally believe that it is fair to say that the president should make the same price equality,” Soriot told reporters on income calls.

Vas Narasimhan, CEO of Novis, at the Swiss-headquarters, said last month that the company was taking an MFN policy to reduce US drug prices.

Meanwhile, a spokesman for Novo Nordisk said the company is “focusing on improving patients’ access and affordability” and “the solution to the solution that helps people to enter the medication they need is continued.”

JP Morgan analysts said in a letter on Friday that the purpose of the latest announcement was to act as a stark warning, while discussions with the American administration could buy some time to respond to pharma companies.

“The latest announcement of the government may seem harsh, but we think the matter is being discussed somewhat between companies and governments, and we believe that pharmaceutical companies will not have much negative impact, analysts said in a letter under the leadership of SEGO Wakao.